Bell Investment Advisors’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Bell Investment Advisors’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-14	Closed	-$1.5K	–	2013
2023 Q1	$1.5K	Buy	14 +4	+40%	+$460	﹤0.01%	1400
2022 Q4	$1.1K	Hold	10	–	–	﹤0.01%	1533
2022 Q3	$1K	Buy	+10	New	+$458	﹤0.01%	1673

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Bell Investment Advisors's RXDX Position: Q2 2023 in Review

Bell Investment Advisors sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 14 shares — an estimated $1.5K sold.

Bell Investment Advisors first reported a position in RXDX in Q3 2022 and held it in 3 quarters. The position peaked at $1.5K in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Bell Investment Advisors reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Bell Investment Advisors sold 14 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $1.5K.
Bell Investment Advisors first reported a position in Prometheus Biosciences, Inc. Common Stock in Q3 2022 and held it in 3 quarters.
Bell Investment Advisors's Prometheus Biosciences, Inc. Common Stock position peaked at $1.5K in Q1 2023.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Bell Investment Advisors's 13F filing for Q2 2023, filed 9 Aug 2023.